VYNE – vyne therapeutics inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

VYNE

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

11/18

08:07 am

vyne

VYNE Therapeutics Inc. (NASDAQ: VYNE) is now covered by analysts at BTIG Research. They set a "buy" rating and a $8.00 price target on the stock.

Low Report

VYNE Therapeutics Inc. (NASDAQ: VYNE) is now covered by analysts at BTIG Research. They set a "buy" rating and a $8.00 price target on the stock.

Report

11/9

08:42 am

vyne

VYNE Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]

Low Report

VYNE Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]

Report

11/8

08:46 am

vyne

VYNE Therapeutics Inc. (NASDAQ: VYNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.75 price target on the stock.

Low Report

VYNE Therapeutics Inc. (NASDAQ: VYNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.75 price target on the stock.

Report

11/7

08:00 am

vyne

VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Medium Report

VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Report

9/26

07:08 am

vyne

We Think VYNE Therapeutics (NASDAQ:VYNE) Needs To Drive Business Growth Carefully [Yahoo! Finance]

Low Report

We Think VYNE Therapeutics (NASDAQ:VYNE) Needs To Drive Business Growth Carefully [Yahoo! Finance]

Report

9/12

12:14 pm

vyne

VYNE Therapeutics Inc. (NASDAQ: VYNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.75 price target on the stock.

Medium Report

VYNE Therapeutics Inc. (NASDAQ: VYNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.75 price target on the stock.

Report

9/12

08:00 am

vyne

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

Medium Report

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

Report

9/3

08:00 am

vyne

VYNE Therapeutics to Participate in September Investor Conferences

Medium Report

VYNE Therapeutics to Participate in September Investor Conferences

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.